The influence of conservative surgical practices for malignant ovarian germ cell tumors

Journal of Surgical Oncology

Volumn 98, Issue 2, 2008, Pages 111-116

  Chan, John K ^a   Tewari, Krishnansu S ^b   Waller, Sarah ^c   Cheung, Michael K ^a   Shin, Jacob Y ^a   Osann, Kathryn ^b   Kapp, Daniel S ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Germ cell tumors; Ovarian cancer; Surgical practice

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; CHILD; CONSERVATIVE TREATMENT; DATA ANALYSIS; DYSGERMINOMA; FEMALE; FEMALE FERTILITY; GERM CELL TUMOR; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONSET AGE; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STATISTICAL SIGNIFICANCE; TERATOMA; YOLK SAC TUMOR;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFERTILITY, FEMALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; SEER PROGRAM; SURVIVAL ANALYSIS;

EID: 49149112674     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21079     Document Type: Article

References (21)

1. Tewari KS, Disaia PJ: On the evolution of a successful treatment program for a solid tumor system. Eur J Gynaecol Oncol 2000;21:339-347.
2. Williams SD, Kauderer J, Burnett AF, et al.: Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: A trial of the Gynecologic Oncology Group. Gynecol Oncol 2004;95:496-499.
3. Feuer EJ, Frey CM, Brawley OW, et al.: After a treatment breakthrough: A comparison of trial and population-based data for advanced testicular cancer. J Clin Oncol 1994;12:368-377.
4. Billmire D, Vinocur C, Rescorla F, et al.: Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: An intergroup study. J Pediatr Surg 2004;39:424-429; discussion 424-9.
5. Cushing B, Giller R, Cullen JW, et al.: Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: A pediatric intergroup study - Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol 2004;22:2691-2700.
6. Dimopoulos MA, Papadimitriou C, Hamilos G, et al.: Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: A prospective multicenter study. Gynecol Oncol 2004;95:695-700.
7. Smith HO, Berwick M, Verschraegen CF, et al.: Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol 2006;107:1075-1085.
8. Surveillance Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2002), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch.
9. Ederer F, Axtell LM, Cutler SJ: The relative survival rate: A statistical methodology. Natl Cancer Inst Monogr Sep 1961;6:101-121.
10. Chan JK, Munro EG, Cheung MK, et al.: Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol 2007;109:12-19.
11. Gershenson DM: Fertility-sparing surgery for malignancies in women. J Natl Cancer Inst Monogr 2005; 43-47.
12. Gershenson DM; Menstrual and reproductive function after treatment with combination chemotherapy for malignant ovarian germ cell tumors. J Clin Oncol 1988;6:270-275.
13. Brewer M, Gershenson DM, Herzog CE, et al.: Outcome and reproductive function after chemotherapy for ovarian dysgerminoma. J Clin Oncol 1999;17:2670-2675.
14. Low JJ, Perrin LC, Crandon AJ, et al.: Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer 2000;89:391-398.
15. Zanetta G, Bonazzi C, Cantu M, et al.: Survival and reproductive function after treatment of malignant germ cell ovarian tumors. J Clin Oncol 2001;19:1015-1020.
16. Tangir J, Zelterman D, Ma W, et al.: Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary. Obstet Gynecol 2003;101:251-257.
17. Tewari KS, Di Saia PJ: Ovulatory failure, fertility preservation and reproductive strategies in the setting of gynecologic and non-gynecologic malignancies. Eur J Gynaecol Oncol 2006;27:449-461.
18. Tyler CW, Jr., Lee NC, Robboy SJ, et al.: The diagnosis of ovarian cancer by pathologists: How often do diagnoses by contributing pathologists agree with a panel of gynecologic pathologists? Am J Obstet Gynecol 1991;164:65-70.
19. Hankey BF, Ries LA, Edwards BK: The surveillance, epidemiology, and end results program: A national resource. Cancer Epidemiol Biomarkers Prev 1999;8:1117-1121.
20. North American Association of Central Cancer Registries. Available at: http://www.naaccr.org/.
21. Virnig BA, Warren JL, Cooper GS, et al.: Studying radiation therapy using SEER-Medicare-linked data. Med Care 2002;40:IV-49-54.